Abstract
The discovery of microRNAs (miRNAs) has shed new light on the role of RNA in gene regulation. MiRNAs are small molecules (size, 19–22 nucleotides) that do not encode proteins but interfere with translation and transcription, thereby regulating gene expression. Multiple miRNAs are dysregulated in human cancer, supporting the hypothesis that miRNAs are involved in the initiation and progression of cancer. Prototypic malignancies in which a role for miRNAs has been demonstrated include chronic lymphocytic leukemia, multiple myeloma, cutaneous T-cell lymphoma and mantle cell lymphoma. More research is necessary, but miRNAs have already improved our understanding of the pathogenesis of cancer. MiRNAs measured in bodily fluids, especially plasma, may be useful as biomarkers for cancer. Beyond miRNAs, several thousand other non-coding (also called ultraconserved) RNAs may be important in the pathogenesis and prognosis of cancer. Some ultraconserved non-coding RNAs interfere with signal transduction by modifying chromatin structures, but most are not yet well characterized. MiRNAs and other non-coding RNAs may be useful for the gene therapy of cancer.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Calin GA, Dumitru C, Shimizu M, et al (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99:15524–15529
Lu J, Getz G, Miska EA, et al (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838
Volinia S, Calin GA, Liu CG, et al (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103:2257–2261
Calin GA, Sevignani C, Dumitru CD, et al (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101:2999–3004
Munker R, Calin GA (2011) MicroRNAs and Cancer. Encyclopedia of Life Science. doi: 10.1002/9780470015902.a0023161
Zhou H, Huang X, Cui H, et al (2010) miR-155 and its star form partner miR-155* cooperatively regulate type I interferon production by human plasmacytoid dendritic cells. Blood 116:5885–5894
Krol J, Loedige I, Filipowicz W (2010) The widespread regulation of MicroRNA biogenesis, function and decay. Nature Rev Genet 11:597–610
Calin GA, Dumitru C, Shimizu M, et al (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99:15524–15529
Calin GA, Ferracin M, Cimmino A, et al (2005) MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353:1793–1801
Scalione BJ, Salerno E, Balan M, et al (2007) Murine models of chronic lymphocytic leukaemia: role of microRNA-16 in the New Zealand black mouse model. Br J Haematol 139: 645–657
Klein U, Lia M, Crespo M, et al (2010) The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17:28–40
Santanam U, Zanesi N, Efanov A, et al (2010) Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc Natl Acad Sci USA 107:12210–12215
Ferracin M, Zagatti B, Rizotto L, et al (2010) MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Molecular Cancer 9:123
Fabbri M, Bottoni A, Shimizu M, et al (2011) Association of a microRNA/TP53 feedback circuitry with the pathogenesis and outcome of B-chronic lymphocytic leukemia. J Am Med Assoc 305:59–67
Calin GA, Croce CM (2009) Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. Blood 114:4761–4770
Lőffler D, Brocke-Heidrich K, Pfeifer G, et al (2007) Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of micro-RNA-21 through a highly-conserved enhancer. Blood 110:1330–1333
Pichiorri F, Su SS, Ladetto M, et al (2008) MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 105:12885–12890
Pichiorri F, Su SS, Rocci A, et al (2010) Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 18:367–381
Lionetti L, Agnelli L, Mosca L, et al (2009) Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosom Cancer 48:521–531
Todoerti K, Barbui V, Pedrini O, et al (2010) Pleiotropic antimyeloma activity of ITF2355; inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica 95:260–269
Roccaro AM, Sacco A, Thompson B, et al (2009) MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 113:6669–6680
Zhou Y, Chen L, Barlogie B, et al (2010) High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proc Natl Acad Sci USA 107:7904–7909
Ballabio E, Mitchell T, van Kester MS, et al (2010) MicroRNA expression in Sézary syndrome: identification, function and diagnostic potential. Blood 116:1105–1113
Zhao JJ, Lin J, Lwin T, et al (2010) microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 115:2630–2639
Di Lisio L, Gómez-López G, Sanchez-Beato M, et al (2010) Mantle cell lymphoma: transcriptional regulation by microRNAs. Leukemia 24:1335–1342
Mitchell PS, Parkin RK, Kroh EM, et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513–10518
Ng EKO, Chong WWS, Jin H, et al (2009) Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58:1375–1381
Silva J, Garcỉa V, Zaballos Ấ, et al (2010) Vesicle-related microRNAs in plasma of NSCLC patients and correlation with survival. Eur Resp J Express E-pub. (July 2010) doi:10.1183/09031936.00029610
Li A, Omura N, Hong SM, et al (2010) Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 70:5226–5237
Heneghan HM, Miller N, Kelly R, et al (2010) Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 15:673–682
Weber JA, Baxter DH, Zhang S, et al (2010) The MicroRNA spectrum in 12 body fluids. Clin Chem 56:1733–1741
Malecová B, Morris KV (2010) Transcriptional gene silencing mediated by non-coding RNAs. Curr Opin Mol Ther 12:214–222
Calin GA, Liu CG, Ferracin M, et al (2007) Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 12:215–229
Lujambio A, Portela A, Liz J, et al (2010) CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncog 29:6390–6401
Huarte M, Rinn JL (2010) Large non-coding RNAs: missing links in cancer? Hum Molec Genetics 19:R152–R161
Ji P, Diederichs S, Wang W, et al (2003) MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncog 22:8031–8041
Lin R, Maeda S, Liu C, et al (2007) A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncog 26:851–858
Fellenberg J, Barnd L, Delling G, et al (2007) Prognostic significance of drug-related genes in high-grade osteosarcoma. Modern Pathol 20:1085–1094
Tano K, Mizuno R, Okada T, et al (2010) MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEBS Lett 584:4575–4580
Gupta RA, Shah N, Wang KC, et al (2010) Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464:1071–1076
Yoshimizu T, Miroglio A, Ripoche MA, et al (2008) The H19 locus acts in vivo as a tumor suppressor. Proc Natl Acad Sci USA 105:12417–12422
Sirchia SM, Tabano S, Monti L, et al (2009) Misbehaviour of XIST RNA in breast cancer cells. PLoS 4:5559
Parrott AM, Tsai M, Batchu P, et al (2010) The evolution and expression of the snaR family of small non-coding RNAs. Nucl Ac Res E-pub 39: 1485–1500
Mestdagh P, Fredlund E, Pattyn F, et al (2010) An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours. Oncogene 29:3583–3592
Chung S, Nakagawa H, Uemura M, et al (2011) Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci 102:245–252
Matouk IJ, Abbasi I, Hochberg A, et al (2009) Highly upregulated in liver cancer noncoding RNA is overexpressed in hepatic colorectal metastasis. Eur J Gastroenterol Hepatol 21:688–692
Romanuik TL, Wang G, Morozowa O, et al (2010) LNCaP atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer. BMC Medical Genomics 3:43
Braconi C, Valeri N, Kogure T, et al (2011) Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci USA 108:786–791
Li Y, Guessous F, Zhang Y, et al (2009) MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 69:7569–7576
Wiggins JF, Ruffino L, Kelnar K, et al (2010) Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 70:5923–5930
Elyakim E, Sitbon E, Faerman A, et al (2010) hsa-miR-191 is a candidate oncogene target for hepotocellular carcinoma therapy. Cancer Res 70:8077–8087
Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327:198–201
Acknowledgments
G.A.C. is supported as a Fellow at The University of Texas MD Anderson Research Trust, as a Fellow of The University of Texas System Regents Research Scholar program and by the CLL Global Research Foundation. Work in Dr Calin’s laboratory is supported in part by the National Institutes of Health (including MD Anderson’s Cancer Center Support Grant, CA016672), by a Department of Defense Breast Cancer Idea Award, by Developmental Research Awards in Breast Cancer, Ovarian Cancer and Leukemia Specialized Programs of Research Excellence, by a CTT/3I-TD grant and by a 2009 Seena Magowitz—Pancreatic Cancer Action Network—AACR Pilot Grant. R.M. is supported by Louisiana State University, Shreveport (sabbatical leave). Sunita C. Patterson helped with editing.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Munker, R., Calin, G. (2013). MicroRNAs and Other Non-Coding RNAs: Implications for Cancer Patients. In: Alahari, S. (eds) MicroRNA in Cancer. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-4655-8_1
Download citation
DOI: https://doi.org/10.1007/978-94-007-4655-8_1
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-4654-1
Online ISBN: 978-94-007-4655-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)